HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Civamide cream 0.075% in patients with osteoarthritis of the knee: a 12-week randomized controlled clinical trial with a longterm extension.

AbstractOBJECTIVE:
To evaluate the safety and efficacy of civamide cream 0.075% for the treatment of osteoarthritis (OA) of the knee.
METHODS:
We conducted a 12-week, multicenter, randomized, double-blind study with a 52-week open-label extension. Patients with OA of the knee received either civamide cream 0.075% or a lower dose of civamide cream, 0.01%, as the control. The 3 co-primary endpoints in the double-blind study were the time-weighted average (TWA) of change from baseline to Day 84 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, the WOMAC physical function subscale, and the Subject Global Evaluation (SGE). In the 52-week open-label extension study, the Osteoarthritis Pain Score and SGE were assessed.
RESULTS:
A total of 695 patients were randomized to receive civamide cream 0.075% (n = 351) or civamide cream 0.01% (control; n = 344) in the double-blind study. Significance in favor of civamide cream 0.075% was achieved for the TWA for all 3 co-primary efficacy variables: WOMAC pain (p = 0.009), WOMAC physical function (p < 0.001), and SGE (p = 0.008); and at Day 84 for these 3 variables (p = 0.013, p < 0.001, and p = 0.049, respectively). These analyses accounted for significant baseline-by-treatment interactions. In the 52-week open-label extension, efficacy was maintained. Civamide cream 0.075% was well tolerated throughout the studies.
CONCLUSION:
These studies demonstrate the efficacy of civamide cream for up to 1 year of continuous use. Civamide cream, with its lack of systemic absorption, does not have the potential for serious systemic toxicity, in contrast to several other OA treatments.
AuthorsThomas J Schnitzer, Jean-Pierre Pelletier, Doug M Haselwood, William T Ellison, John E Ervin, Richard D Gordon, Jeffrey R Lisse, W Tad Archambault, Allan R Sampson, Heidi B Fezatte, Scott B Phillips, Joel E Bernstein
JournalThe Journal of rheumatology (J Rheumatol) Vol. 39 Issue 3 Pg. 610-20 (Mar 2012) ISSN: 0315-162X [Print] Canada
PMID22089461 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • zucapsaicin
  • Capsaicin
Topics
  • Administration, Topical
  • Adult
  • Aged
  • Capsaicin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Knee Joint (physiopathology)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Osteoarthritis, Knee (drug therapy, physiopathology)
  • Time Factors
  • Treatment Outcome
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: